

Global Hemp Group Inc.

Condensed Consolidated Interim Financial Statements

Three Months Ended December 31, 2020

Unaudited

Expressed in Canadian Dollars









For Further Information Contact

Tel: 424-354-2998

info@globalhempgroup.com

www.globalhempgroup.com

NOTICE TO READER

In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the accompanying condensed consolidated interim financial statements.

Consolidated Statements of Financial Position (Unaudited – expressed in Canadian dollars)

		December 31, 2020	September 30, 2020 (Audited)
	Note		
		\$	\$
Assets			
Current assets			
Cash	4	315,428	16,372
Accounts receivable		33,289	32,203
Income tax receivable		15,915	_
Assets held for sale		- -	5,000
Biological assets	6	39,177	470
Deposits and prepayments		84,274	10,878
		488,083	64,923
Property and equipment	7	2,258,923	2,358,599
TOTAL ASSETS		\$ 2,747,006	\$ 2,423,522
Current liabilities Accounts payable and accrued liabilities Customer advances	5 & 9	450,093	677,461 5,000
Notes payable	11	706,476	826,426
Total liabilities		1,156,569	1,508,887
Shareholders' deficiency			
Share capital	10	7,856,143	7,118,029
Shares to be issued		_	25,500
Reserve		4,310,944	4,146,388
Deficit		(10,532,251)	(10,332,482)
Total equity attributable to owners of parent		1,634,836	957,435
Non-controlling interest		(44,399)	(42,800)
		1,590,437	914,635
Total liabilities and shareholders' equity		\$ 2,747,006	\$ 2,423,522

The accompanying notes are an integral part of these condensed interim consolidated financial statements

Nature of operations and going concern (Note 1) Event after the reporting period (Note 17)

Approved and authorized for issuance by the Board of Directors on March 1, 2021

"Curt Huber"
Director

"Jeff Kilpatrick"
Director

Consolidated Statements of Comprehensive Loss (Unaudited – expressed in Canadian dollars)

(Chaudhed Capressed in Canadian donars)		Three months ende	ded December 31,	
	Note	2020	2019	
		\$	\$	
Gross Revenue		-	28,875	
Cost of Goods Sold		-	10,351	
Gross Profit		-	18,524	
Expenses				
Advertising and promotion		6,301	293	
Amortization	7	7,151	5,457	
Insurance		3,470	_	
Interest & Bank Charges		8,133	1,276	
Loan inducement fee	11	16,500		
Consulting	9	2,559	21,378	
Office and administration		2,036	442	
Rent		2,000	3,000	
Professional fees		18,040	4,845	
Repair and maintenance		2,276	_	
Research & Development		_,_, -	32,854	
Share based compensation	10	164,682	912,600	
Shareholder communication	10	1,250	<i>-</i> -	
Travel		=	3,373	
Trust and filing fees		4,518	8,354	
(Loss) before other items:		(240,440)	(975,348)	
Exchange gain (loss)		9,511	(20,009)	
Bad debt recovery		657	(20,00)	
Gain (loss) on sale of assets held for sale		751	_	
Gain on sale of equipment		2,094	_	
Share of profit (loss) of Investment in Associates	6	2,001	(21,404)	
Net loss	<u> </u>	(227,427)	(1,016,761)	
Current income tax (recovery)		26,059	(1,010,701)	
Net loss after tax recovery		(201,368)	(1,016,761)	
Other comprehensive (loss) income		(201,300)	(1,010,701)	
Translation adjustment		(49,812)	_	
Comprehensive Loss		(251,180)	(1,016,761)	
Compression C 2000		(201,100)	(1,010,701)	
Net loss attributable to:				
Shareholders of the Company		(199,769)	(1,013,476)	
Non-controlling interest		(1,599)	(3,285)	
Other comprehensive loss attributable to:				
Shareholders of the Company		(49,812)	_	
Non-controlling interest		_	_	
Total comprehensive loss attributable to:				
Shareholders of the Company		(249,581)	(1,013,476)	
Non-controlling interest		(1,599)	(3,285)	
Loss per share, basic and diluted		(0.00)	(0.01)	
Weighted average number of outstanding shares		224,912,606	188,197,016	
<u> </u>		,,	,	

The accompanying notes are an integral part of these consolidated financial statements

Consolidated Statements of Changes in Equity
(Unaudited – expressed in Canadian dollars except for number of shares)

	_	Share Cap	oital		Reser	ve	_	Equity attrib	outable to
				Shares to be	Share-based	Foreign currency		Shareholders'	Non- controlling
	Note	Number	Amount	issued	payment reserve	translation	Deficit	equity	Interest
			\$		\$	\$	\$	\$	\$
Balance, September 30, 2019		188,197,016	6,691,986	-	3,664,283	-	(9,062,732)	1,293,537	65,668
Share-based compensation		_	-	-	912,600	-	-	912,600	_
Net and comprehensive loss		_	-	-	-	-	(1,013,476)	(1,013,476)	(3,285)
Balance, December 31, 2019		188,197,016	6,691,986	_	4,576,883	_	(10,076,208)	1,192,661	62,383
Balance, September 30, 2020		211,660,432	7,118,029	25,500	4,149,362	(2,974)	(10,332,482)	957,435	(42,800)
Share-based compensation	10	_	_	-	164,682	-	-	164,682	_
Loans inducement	11	2,100,000	42,000	(25,500)	-	-		16,500	_
Shares issued of private placements	10	53,200,000	696,114	_	49,686	_	-	745,800	_
Net and comprehensive loss		_		-		(49,812)	(199,769)	(249,581)	(1,599)
Balance, December 31, 2020		266,960,432	7,856,143	_	4,363,730	(52,786)	(10,532,251)	1,634,836	(44,399)

The accompanying notes are an integral part to these condensed interim consolidated financial statements

Consolidated Statements of Cash Flows (Unaudited – expressed in Canadian dollars)

	Three months ended December 33		
	2020	2019	
Cash (used in) provided by:	\$	\$	
Operating activities			
Loss for the period	(201,368)	(1,016,761)	
Non-cash items			
Amortization	7,151	5,457	
Current income tax recovery	(26,059)	_	
Share based compensation	164,682	912,600	
Loan inducement fees	16,500	_	
Gain on sale of assets held for sale	(750)	_	
Gain on sale of equipment	(2,094)	_	
Unrealized foreign exchange (gain) loss	(9,511)	20,009	
Share of (profit) loss of Joint Ventures	_	21,404	
Interest accrual	7,481	551	
Changes in non-cash operating working capital			
Biological assets	(38,707)	_	
Deposits and prepayments	(73,396)	_	
Accounts receivable and sales tax receivable	_	(2,874)	
Accounts payable and accrued liabilities	(139,132)	(5,757)	
Due to related parties	(75,205)	_	
Cash used in operating activities	(370,408)	(65,371)	
Financing activites			
Proceeds from common shares issuance	738,300	_	
Proceeds from promissory note	15,000	_	
Repayments of promissory notes	(103,342)	_	
Cash provided by financing activities	649,958	_	
Investing activities			
Investment in joint venture	_	(213,581)	
Proceeds on disposal of equipment	9,245	(213,301)	
Proceeds on disposal of assets held for sale	750	_	
Cash used in investing activities	9,995	(213,581)	
Cash asea in investing activities	7,775	(213,301)	
Effect of foreign exchange	9,511	(20,009)	
Change in cash	289,545	(278,952)	
Cash, beginning of the year	16,372	485,774	
Cash, end of the period	315,428	186,813	

The accompanying notes are an integral part of these condensed interim consolidated financial statements

Notes to the Condensed Consolidated Interim Financial Statements Three Month Ended December 31, 2020 (Unaudited - expressed in Canadian Dollars)

1. NATURE OF OPERATIONS AND GOING CONCERN

Global Hemp Group (the "Company" or "GHG") was incorporated on October 30, 2009 in British Columbia, Canada under the name Arris Holdings Inc., and on March 24, 2014 changed its name to Global Hemp Group Inc. The Company is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in the United States.

The Company's registered office is located at #106 – 1169 Mt. Seymour Road, North Vancouver, BC, V7H 2Y4. The Company's common shares are traded on Canadian Securities Exchange under the symbol "GHG", on the Börse Frankfurt under the symbol "GHG", and on the OTC Markets in the United States under the symbol "GBHPF".

These consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of operations. The Company's continuation as a going concern is dependent upon its ability to attain profitable operations and generate funds there from and/or raise equity capital or borrowings sufficient to meet current and future obligations. These factors indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Management intends to finance operating costs over the next twelve months with debt and or private placements of common shares. Should the Company be unable to continue as a going concern, the net realizable value of its assets may be materially less than the amounts on its statement of financial position.

2. STATEMENT OF COMPLIANCE

These condensed consolidated interim financial statements for three months ended December 31, 2020, together with the comparative figures herein have been prepared in accordance with International Accounting Standards ("IAS") 34 "Interim Financial Reporting" ("IAS 34") using accounting policies consistent with the International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC").

These consolidated condensed interim financial statements do not include all of the information required of a full annual financial report and is intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that these condensed interim financial statements be read in conjunction with the audited annual financial statements of the Company for the most recent year ended September 30, 2020.

3. SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

These condensed consolidated interim financial statements have been prepared on an accrual basis and are based on historical costs, except for financial instruments measured at their fair value. These condensed consolidated interim financial statements are presented in Canadian dollars, unless otherwise noted.

Significant estimates and assumptions

The preparation of financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. The Company's management reviews these estimates and

Notes to the Condensed Consolidated Interim Financial Statements

Three Month Ended December 31, 2020

(Unaudited - expressed in Canadian Dollars)

underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.

Estimates where there is significant risk of material adjustments to assets and liabilities in future accounting periods include the fair value measurements for financial instruments, the recoverability and measurement of deferred tax assets and the fair value of inventory.

Significant judgments

The preparation of financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company's financial statements include:

- the assessment of the Company's ability to continue as a going concern and whether there are events or conditions that may give rise to significant uncertainty.

Biological assets

The Company's biological assets consist of hemp plants and are valued using the cost approach. Production costs are capitalized to biological assets and include all direct and indirect costs relating to biological transformation. The Company measures and adjusts the biological assets to cost, up to the point of harvest, which becomes the basis for the cost of finished goods inventories after harvest. Unrealized gains or losses arising from the changes in fair value less cost to sell during the period are included in the results of operations for the related period.

New Accounting standards issued but not yet applied

At the date of the approval of the consolidated financial statements, a number of standards and interpretations were in issue but not yet effective. The Company considers that these new standards and interpretations are either not applicable or are not expected to have a significant impact on the Company's consolidated financial statements.

4. CASH AND CASH EQUIVALENTS

	December 31, 2020	September 30, 2020
	\$	\$
Bank demand deposits	226,403	16,372
Deposit in transit	89,025	
	315,428	16,372

5. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	December 31,	September 30,
	2020	2020
	\$	\$
Trade payables	393,820	393,017
Accrued liabilities	56,273	275,307
Taxes payable	-	9,137
	450,093	677,461

 ${\bf Notes\ to\ the\ Condensed\ Consolidated\ Interim\ Financial\ Statements}$

Three Month Ended December 31, 2020

(Unaudited - expressed in Canadian Dollars)

6. BIOLOGICAL ASSETS

The Company's biological assets consist of hemp plants and the capitalized direct costs for cultivation prior to 2021 harvesting season.

7. EQUIPMENT

			Office	Trucks &	Farming	Incorporation	
	Land	Buildings	furniture	Vehicles	equipment	costs	Total
Cost:	\$	\$	\$	\$	\$		\$
Balance, September 30, 2019	•				353,197	642	353,839
Additions	-	-	-	-	-	-	-
Disposal	-	-	-	-	-	-	-
Balance, December 31, 2019		-	-	•	353,197	642	353,839
Balance, September 30, 2020	1,534,008	538,550	1,694	47,701	236,288	642	2,358,883
Disposal	-	-	-	-	(5,382)		, ,
Foreign currency translation	(48,419)	(17,433)	(82)	(2,238)	(12,530)	-	(80,702)
Balance, December 31, 2020	1,485,589	521,117	1,612	45,463	218,376	642	2,278,181
Amortization:							
Balance, September 30, 2019	_	_	_	-	134,927	_	134,927
Change for the period		_	_	_	5,457		5,457
Balance, December 31, 2019				•	140,384	•	140,384
Balance, September 30, 2020		113	2	30	139	_	284
Disposal		-	_	-	-	-	-
Change for the period	-	7,273	82	1,207	5,587		14,149
Foreign currency translation		(228)	(4)	(58)	(267)	-	(557)
Balance, December 31, 2020		7,158	80	1,179	5,459	-	13,876
Net book value:							
At December 31, 2020	1,485,589	513,959	1,532	44,284	212,917	642	2,258,923
At December 31, 2019	-	-	-	-	212,813	642	218,912

Notes to the Condensed Consolidated Interim Financial Statements

Three Month Ended December 31, 2020

(Unaudited - expressed in Canadian Dollars)

8. INVESTMENT IN JOINT VENTURES

	CBA Oregon	41389 Farms	Total
Balance as at September 30, 2019	536,303	525,076	1,061,379
Contributions - cash	169,445	44,135	213,580
Share of profit or (loss) for the period	(13,106)	(8,297)	(21,403)
Balance as at December 31, 2019	692,642	560,914	1,253,556

Balance as at September 30, 2020 & December 31, 2020

a) Scio, Oregon Project

Incorporation of 41389 Farms Ltd and Acquisition of Agricultural Property

On March 23, 2018, the Scio, Oregon Project was incorporated as an Oregon Corporation. The Company held 50% of the shares and the other 50% were held by MCOA until September 28, 2020 when the Company acquired a 100% interest (Note 7 to the audited financial statements for the year ended September 30, 2020).

b) CBA Oregon

On May 8, 2018, the Company and MCOA entered into a joint venture agreement for the development of a hemp farm. CBA Oregon was incorporated under the laws of Oregon State on April 19, 2018. The Company held 50% of the shares and the other 50% were held by MCOA until September 28, 2020 when the Company acquired a 100% interest (Note 7 to the audited financial statements for the year ended September 30, 2020).

9. RELATED PARTY TRANSACTIONS

Key Management Compensation:

	NT 4 64 4	Three months ended December 31
	Nature of transactions	2020 201
		\$
CFO	Accounting fees	1,500 1,50
Director	Legal fees	14,591 4,97
Directors	Share-based compensation	59,809 912,60

Included in accounts payable and accrued liabilities is \$78,545 (September 30, 2020 - \$128,04) due to directors and officers for unpaid consulting fees and expense reimbursements. These amounts are unsecured, non-interest bearing with no fixed payment terms.

During the three months ended December 31, 2020, the Company incurred consulting fees of \$NIL for the service of the President/CEO (Three months ended December 31, 2019 - \$10,000) and recognized share based compensation of \$29,905. The President/CEO participated in the private placement closed on December 11, 2020 (note 10) though a subscription of 6,000,000 units at \$0.015/unit. A balance of \$NIL was owed to the CEO as at December 31, 2020 (September 30, 2020 - \$52,500).

Notes to the Condensed Consolidated Interim Financial Statements Three Month Ended December 31, 2020 (Unaudited - expressed in Canadian Dollars)

During the three months ended December 31, 2020, the Company incurred accounting fees of \$1,500 for the service of the CFO (Three months ended December 31, 2019 - \$1,500). Balance due to the CFO of \$3,500 was recorded as at December 31, 2020 (September 30, 2020 - \$2,000). The balance was subsequently settled in February 2021.

During the three months ended December 31, 2020, the Company incurred legal fees of \$14,591 (Three months ended December 31, 2019 - \$4,970) for the service of a law firm controlled by a director newly appointed in May 2020. A balance of \$41,295 was owed to the law firm as at December 31, 2020 (September 30, 2020 - \$31,078).

During the three months ended December 31, 2020, the Company recognized share based compensation of \$29,904 to a director of the Company (Three months ended December 31, 2019 - \$304,200). A balance of \$18,750 was owed to the director as at December 31, 2020 (September 30, 2020 - \$26,250).

A balance of \$15,000 was owed to the director as at December 31, 2020 (September 30, 2020 - \$15,000).

10. CAPITAL STOCK

Authorized

Unlimited number of common shares and Class B preferred shares without par value.

Issued and outstanding

On October 8, 2020, 1,700,000 common shares of the Company were issued for the loan inducement.

On November 30, 2020, 400,000 common shares of the Company were issued for the loan inducement.

On December 11, 2020, the Company closed a private placement of non-brokered private placement, consisting of 51,600,000 units ("Units") at a price of \$0.015 per Unit for gross proceeds of \$774,000 (the "Private Placement"). Each unit is comprised of one common share of the Company (a "Common Share" and collectively, the "Common Shares") and one common share purchase warrant (each whole warrant a "Warrant" and collectively, the "Warrants") of the Company. Each whole Warrant shall entitle the holder thereof to acquire one additional Common Share at a price of \$0.05 per Common Share for a period expiring on September 8, 2023. The warrants will be listed for trading on the CSE after the expiry of the hold period and will have identical terms to the 11,076,741 listed warrants of the Company currently outstanding and trading under the ticker symbol GHG.WT. In the event that the Company's common shares trade on the Canadian Securities Exchange (or such other exchange on which the common shares may be traded at such time) at a volume weighted average price of \$0.12 per share or more for a period of 10 consecutive trading days, the Company will have the right to accelerate the expiry date of the Warrants by giving notice to the holders thereof and, in such case, the Warrants will expire on the 30th day after the date on which such notice is given to the holder by the Company. All securities issued are subject to a four-month plus a day hold period from the date of issuance in accordance with applicable securities laws.

On December 11, 2020, 1,600,000 common shares and 1,880,000 share purchase warrants of the Company were issued as a finder's fee for this private placement. The 1,880,000 share purchase warrants are exercisable at \$0.05 with the expiry date on September 8, 2023.

During the three months ended December 31, 2019, there were no shares issued or returned to the Company's treasury.

Notes to the Condensed Consolidated Interim Financial Statements Three Month Ended December 31, 2020

(Unaudited - expressed in Canadian Dollars)

Warrants

A continuity of the Company's warrants is as follows:

	Number of Warrants	Weighted average exerc price	ise Weighted average number years to expiry
Balance, September 30, 2020	43,642,299	\$ 0.	12 2.49
Granted	53,480,000	\$ 0.	05 2.69
Balance, December 31, 2020	97,122,299	\$ 0.	08 2.60

The fair value of 1,880,000 warrants granted during the three months ended December 31, 2020 related to the finder's fees was determined to be \$49,686 using the Black-Scholes option pricing model with the following assumptions: expected life of 2.74 years, volatility of 203%, dividend yield of 0%, and risk-free rate of 0.30%.

As at December 31, 2020, the Company had the following warrants outstanding:

Date Issued	Expiry Date	Exercise Price	Number of Warrants Outstanding
February 28, 2017	February 28, 2022	\$0.05	1,519,350
March 7, 2018	March 1, 2023	\$0.15	12,376,875
November 29, 2018	July 31, 2021	\$0.36	1,200,000
December 12, 2018	December 10, 2023	\$0.12	16,200,000
February 6, 2019	February 6, 2021	\$0.13	169,333
June 24, 2019	July 31, 2021	\$0.36	1,100,000
September 11, 2020	September 8, 2023	\$0.05	11,076,741
December 11, 2020	September 8, 2023	\$0.05	53,480,000
			97,122,299

Stock options

On November 30, 2020, the Company granted 5,300,000 stock options to external consultants. Each option entitles the holder to purchase one common share of the Company at \$0.05 per share and fully vested on grant date. The expiry date of these options is November 25, 2025. The fair value of these options was determined to be \$101,437 using the Black-Scholes option pricing model with the following weighted average assumptions: expected life of 4.97 years, volatility of 197%, dividend yield of 0%, and risk-free rate of 0.43%.

On August 9, 2019, the Company granted 5,750,000 stock options to directors and consultants. Each option entitles the holder to purchase one common share of the Company at \$0.06 per share. 4,750,000 of the stock options fully vested on the grant date and 1,000,000 vested 25% on grant date and then 25% on each of December 31, 2019, 2020, and 2021. The expiry date of these options is August 8, 2024. The fair value of these options was determined to be \$314,417 using the Black-Scholes option pricing model with the following weighted average assumptions: expected life of 5 years, volatility of 143%, dividend yield of 0%, and risk-free rate of

Notes to the Condensed Consolidated Interim Financial Statements

Three Month Ended December 31, 2020

(Unaudited - expressed in Canadian Dollars)

1.26%. The Company recognized cumulative share based compensation of \$300,746 in connection with this grant.

A continuity of the Company's options is as follows:

	Options	Weighted average exercise price	Weighted average number years to expiry
Balance, September 30, 2020	16,000,000	\$0.072	2.09
Granted	5,300,000	\$0.050	4.90
Balance, December 31, 2020	21,300,000	\$0.054	3.15

As at December 31, 2020, the Company had the following options outstanding:

Date Granted	Expiry Date	Exercise	Number of Options	Number of options
		Price	Outstanding	Exercisable
September 20, 2017	September 20, 2021	\$0.05	7,600,000	7,600,000
September 24, 2018	September 20, 2023	\$0.16	2,650,000	2,650,000
August 9, 2019	August 8, 2024	\$0.06	5,750,000	5,250,000
November 30, 2020	November 25, 2025	\$0.05	5,300,000	5,300,000
			21,300,000	15,500,000

Share based payment reserve

The share-based payment reserve records items recognized as stock-based compensation expense and other share-based payments until such time that the stock options or warrants are exercised, at which time the corresponding amount will be transferred to share capital.

Foreign currency translation reserve

The foreign currency translation reserve records unrealized exchange differences arising on translation of foreign operations that have a functional currency other than the Company's reporting currency.

Basic and diluted loss per share

Diluted loss per share does not include the effect of 97,122,299 warrants and 21,300,000 options as the effect would be anti-dilutive.

11. NOTE PAYABLE

a) 41389 Farms

On April 30, 2018, the vendor of the farmland property held by 41389 Farms issued a promissory note to 41389 Farms in the amount of US\$695,000.

Interest rate

The initial interest rate shall be Four Percent (4.0%) for the period up to September 30, 2018. The interest rate shall be adjusted effective on October 1 of each year during the term of this Note. The

Notes to the Condensed Consolidated Interim Financial Statements

Three Month Ended December 31, 2020

(Unaudited - expressed in Canadian Dollars)

adjusted interest rate will be determined by adding 1.15 percentage points (1.15%) to the Ten Year US Treasury Note as of the market close on September 30 of each year. This amount will be the new interest rate until the next following October I, when the rate shall again be adjusted. The adjusted interest rate for the interest calculation for the fiscal period ended September 30, 2021 was 2.83%.

Payment term

Maker shall make monthly payments to the vendor in the amount of US\$7,036. The first payment was due on June 1, 2018 and subsequent payments due on the first day of each month thereafter, until May 1, 2021, when the entire principal balance and accrued unpaid interest shall be all due and payable.

Any prepayment shall not postpone the due date of any subsequent payments, unless the lender shall otherwise agree in writing. There is no penalty for prepayment. A late payment penalty of 5% shall apply to any payment not made within 15 days of its due date.

Balance due as at December 31 and September 30, 2020

As at December 31, 2020, the principal balance outstanding was \$674,721 (US\$529,941) (September 30, 2020:\$745,221 (US\$558,678)). The entire balance will become due on or before May 1, 2021. The balance due as at September 30, 2019 was included in the investment in joint ventures.

b) Short-term loans

The Company received short term loans in the amount of \$15,000 during the current quarter ended December 31, 2020 and \$50,000 during the fourth quarter of the year ended September 30, 2020. These short-term loans are non-interest bearing loans and were settled by cash repayments of \$25,000 on December 11, 2020, \$7,500 on December 14, 2020 and \$25,000 on December 21, 2020 and through the issuance of common shares valued at \$7,500 on December 6, 2020.

Two tranches of bonus shares totaling 2,100,000 common shares were issued to the Lenders for this transaction as a loan inducement: First tranche of 1,700,000 common shares with total fair value of \$34,000 were recorded on the share issuance date on October 8, 2020 whereby the Company recognized fair value of \$25,500 of the \$34,000 during the fiscal year ended September 30, 2020. Second trance of 400,000 common shares with fair value of \$9,000 were recorded on the share issuance date on November 30, 2020.

c) Innovative Inc.

On December 1, 2014, the Company converted \$18,355 of its accounts payable owing to a company ("Lender"), controlled by the relative of a former director, into a promissory note. This promissory note is payable on demand and bears interest of 12% per annum. The promissory note is secured by a general and continuing collateral security in favor of the Lender. As of December 31, 2020, the Company had a balance payable of \$31,755 (September 30, 2020-\$31,205).

12. NON-CONTROLLING INTEREST

The non-controlling interest consists of 50% ownership of 703551 N.B Ltd., which was incorporated on July 5, 2018.

The following is the summarized statement of financial position of 703551 N.B. Ltd, as at December 31, 2020 and 2019:

Notes to the Condensed Consolidated Interim Financial Statements

Three Month Ended December 31, 2020

(Unaudited - expressed in Canadian Dollars)

	December 31,	September 30,	
	2020	2020	
Current:		\$	
Assets	1,578	5,038	
Total current net assets	1,578	5,038	
Non-current			
Assets	643	642	
Total non-current net assets	643	642	
Total net contributions by partners	2,221	5,680	

The following is the summarized comprehensive loss of 703551 N.B. Ltd, for the current quarter and the same quarter of fiscal 2020.

	Three months ended December 31, 2020	Three months ended December 31, 2019		
	\$	\$		
Revenue	_	_		
Costs of sales recovery	_	_		
Operating expenses	(3,949)	(6,569)		
Gain on assets held for sale	751			
Net loss	(3,198)	(494,538)		

13. SEGMENT DISCLOSURE

The Company operates in one operating segment, which is acquisition, and operation of hemp related projects. The following provides segmented disclosure on the non-current assets by geographic locations:

Notes to the Condensed Consolidated Interim Financial Statements

Three Month Ended December 31, 2020

(Unaudited - expressed in Canadian Dollars)

SEGMENT DISCLOSURE (ROUNDED TO 000s)	Canada	U	nited States	Total
December 31, 2020				
Revenue	\$ _	\$	_	\$ _
Long-term Assets				
Property and equipment	\$ 1,000	\$	2,358,000	\$ 2,359,000
December 31, 2019				
Revenue	\$ _	\$	28,000	\$ 28,000
Long-term Assets				
Investments in Joint Venture	\$ _	\$	1,254,000	\$ 1,254,000
Property and equipment	\$ _	\$	213,000	\$ 213,000

14. FINANCIAL INSTRUMENTS

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:

Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company's primary exposure to credit risk is on its cash. As most of the Company's cash is held by one bank, there is a concentration of credit risk. This risk is managed by using a major bank that is a high credit quality financial institution as determined by rating agencies.

Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company's joint venture operations are located in the United States and at December 31, 2020 the Company has cash of \$549 denominated in US dollars.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to interest rate risk is minimal.

Liquidity Risk

Liquidity risk is the risk that the Company may be unable to meet its financial obligations as they fall due. The Company reviews its working capital position regularly to ensure there is sufficient capital in order to meet short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash. Liquidity risk is assessed as high.

Fair value

The Company categorizes its financial instruments measured at fair value using a hierarchy based on the inputs used to measure fair value. The fair value hierarchy has three levels based on the reliability of the inputs used to determine fair value as follows:

Notes to the Condensed Consolidated Interim Financial Statements Three Month Ended December 31, 2020 (Unaudited - expressed in Canadian Dollars)

Level 1: observable inputs such as quoted prices in active markets;

Level 2: inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3: unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The fair value of the Company's financial assets and liabilities approximates the carrying amount due to their short term nature.

15. CAPITAL MANAGEMENT

The Company's policy is to maintain a strong capital base so as to maintain investor and creditor confidence, safeguard the Company's ability to support the Company's activity in agriculture and manufacturing in the industrial hemp sector and to sustain future development of the business. The capital structure of the Company consists of working and share capital.

There are no restrictions on the Company's capital and there were no changes in the Company's approach to capital management during the year.

16. COVID-19 (CORONAVIRUS)

On March 11, 2020, the current outbreak of COVID-19 (Coronavirus) was declared a global pandemic, which has had a significant impact on businesses through the restrictions put in place by the Canadian, provincial and municipal governments regarding travel, business operations and isolation/quarantine orders. As a result, global equity markets and oil prices have experienced significant volatility and weakness. At this time, it is unknown the extent of the impact the COVID-19 outbreak may have on the Company as this will depend on future developments that are highly uncertain and that cannot be predicted with confidence. These uncertainties arise from the inability to predict the ultimate geographic spread of the disease, and the duration of the outbreak, including the duration of travel restrictions, business closures or disruptions, and quarantine/isolation measures that are currently, or may be put, in place by Canada and other countries to fight the virus.

17. EVENTS AFTER THE REPORTING DATE

(a) Acquisition of Preferred Shares of Western Sierra Resource Corporation

On February 8, 2021, the Company announced that it had signed a Definitive Agreement with Prescient Strategies Group LLC ("PSG") to acquire all of its Western Sierra Resource Corporation (OTC: WSRC) ("WSRC") Series A Preferred Shares ("WSRC Prefs") in a private, third party transaction.

Transaction Details:

Prescient Strategies Group LLC currently holds 19,875,000 WSRC Prefs (with Voting Rights of 100 votes per share). On closing of the Definitive Agreement, GHG will acquire 11,006,440 unencumbered WSRC Prefs from PSG for 11,006,400 GHG Preferred B shares ("GHG Prefs") (the "Initial Issuance"), as more fully outlined below.

An additional 8,868,560 WSRC Prefs have been pledged as collateral to secure US\$3,842,269 loans to WSRC (the "Loan"). These encumbered WSRC Prefs will also be acquired by GHG upon the restructuring WSRC's existing debt (the "WSRC Debt") by way of, but not limited to, the consolidation, refinance or extension of the existing WSRC Debt (the "WSRC Debt Restructuring"). Further to the WSRC Debt Restructuring, the WSRC Debt will have a maturity of a minimum of three (3) years, with the objective of replacing existing notes and releasing the WSRC Prefs as collateral.

Notes to the Condensed Consolidated Interim Financial Statements

Three Month Ended December 31, 2020

(Unaudited - expressed in Canadian Dollars)

As part of the contemplated transaction, GHG will issue 10,000,000 common share purchase warrants to PSG (the "GHG Warrants"). The GHG Warrants will be exercisable for a period of five (5) years at a price per GHG Warrants of CAD\$0.05 per share.

GHG Pref Details:

The GHG Prefs shall have a par value of US\$0.50 per preferred share and a maturity date of ten (10) years following their issuance. The GHG Prefs will be non-voting, will pay an annual dividend of US\$0.01 per share, paid in cash or shares at the option of the holder, and will be convertible into two (2) common shares of GHG for every GHG Pref held by each holder thereof.

The GHG Prefs will be secured by the WSRC Prefs. The GHG Prefs are redeemable by GHG at face value plus any accrued and unpaid dividends any time after the refinancing of the WSRC Debt and the term of the WSRC Debt has been extended to a period of at least three (3) years.

Should PSG decide to sell its GHG Prefs in a private third party transaction, GHG will be granted a thirty day Right of First Refusal (the ''GHG ROFR'') to match any *bona fide* offer by a third-party, before PSG can act on such third-party offer.

Closing of the transaction is expected to be on or about late February to early March of 2021 upon fulfillment of certain Conditions Precedent, including:

- WSRC restructuring certain unsecured debt prior to the issuance of the GHG Prefs;
- GHG providing the necessary initial payments to complete the transaction and other Debt Restructuring (completed).

The resulting acquisition of these WSRC Prefs will give GHG control over WSRC, and specifically its strategic water infrastructure assets that will be an integral part of the Company's Colorado Hemp-Agro Industrial Zone ("HAIZ") project. Documented historical valuations of the 4,000 acre feet of water rights and associated infrastructure are based on 2013 and 2015 MAI appraisals and engineering reports, which collectively support a value of US\$40,000,000 or higher. GHG has contracted a third party valuation of this initial assessment value to support such appraisal.

(b) Issuance of stock options

On January 25, 2021, 5,300,000 options were issued with an exercise price of \$0.055 and expiry date of January 25, 2026.

On January 27, 2021 the Company cancelled 2,500,000 stock options granted to Directors, management and consultants on September 24, 2018. The exercise price of the cancelled stock option was \$0.16 per share. The stock options were voluntarily surrendered by the holders for no consideration.

On January 27, 2021, 2,500,000 options were granted to directors, management and consultants exercisable at a price of \$0.06 per share. These options vested on the date of grant and have a term of five years.